However, in a post hoc analysis of patients who had prior CD19‐directed therapies before receiving liso‐cel in TRANSCEND NHL 001, 92% achieved responses with no apparent effects on cellular kinetics.31 Here, CD19 is linked to non-Hodgkin lymphoma.